Search details
1.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
N Engl J Med
; 388(8): 719-732, 2023 02 23.
Article
in English
| MEDLINE | ID: mdl-36795891
2.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Article
in English
| MEDLINE | ID: mdl-35179323
3.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Article
in English
| MEDLINE | ID: mdl-37285865
4.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Oncologist
; 29(3): 235-243, 2024 Mar 04.
Article
in English
| MEDLINE | ID: mdl-37812679
5.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Article
in English
| MEDLINE | ID: mdl-38394384
6.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 385(12): 1091-1103, 2021 09 16.
Article
in English
| MEDLINE | ID: mdl-34161051
7.
Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
Curr Oncol Rep
; 26(5): 488-495, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38592590
8.
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
Future Oncol
; 20(9): 493-505, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37882449
9.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(6): 597-610, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37269841
10.
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Lancet Oncol
; 24(7): 783-797, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37414011
11.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
; 399(10336): 1695-1707, 2022 04 30.
Article
in English
| MEDLINE | ID: mdl-35405085
12.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
N Engl J Med
; 383(11): 1040-1049, 2020 09 10.
Article
in English
| MEDLINE | ID: mdl-32905676
13.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 383(24): 2345-2357, 2020 12 10.
Article
in English
| MEDLINE | ID: mdl-32955174
14.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(23): 2197-2206, 2020 06 04.
Article
in English
| MEDLINE | ID: mdl-32469184
15.
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(22): 2091-2102, 2020 05 28.
Article
in English
| MEDLINE | ID: mdl-32343890
16.
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
J Urol
; 209(3): 532-539, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36756959
17.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Future Oncol
; 19(29): 1953-1960, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37585665
18.
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
Future Oncol
; 19(12): 819-828, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-37222151
19.
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(3): 393-405, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35157830
20.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 362-373, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35131040